Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268719 | 0.88 | MAOB (0.81) | MAOBCYP4F2CYP4A11BCHEMAOA | |
| SCHEMBL15425251 | 0.86 | CYP4F2 (0.63) | MAOBCYP4F2CYP4A11BCHEMAOA | |
| SCHEMBL23989 | 0.84 | MAOB (0.60) | MAOBMAOANR4A2MEN1KMT2A | |
| SCHEMBL22875 | 0.83 | MAOB (0.68) | MAOBBCHEMEN1KMT2A | |
| SCHEMBL21409 | 0.83 | MAOB (0.61) | MAOBMAOANR4A2 | |
| SCHEMBL22564 | 0.83 | MAOB (0.64) | MAOBBCHESMPD1SPHK2 | |
| SCHEMBL28237963 | 0.82 | MAOB (0.72) | MAOBCYP4F2CYP4A11BCHEMAOA | |
| SCHEMBL5329319 | 0.82 | MAOB (0.72) | MAOBCYP4F2CYP4A11BCHEMAOA | |
| SCHEMBL28182081 | 0.82 | MAOB (0.79) | MAOBCYP4F2CYP4A11BCHEMAOA | |
| SCHEMBL306550 | 0.82 | LMNA (0.64) | MAOBBCHEMAOANR4A2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293553-A1 | P-SELECTIN INHIBITORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2023049265-A1 | P-SELECTIN INHIBITORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-113861188-B | Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor | 杭州医学院 | 2023-02-28 | — | — | CN | disclosed |
| CN-108884083-B | Benzo [ B ] furans as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113861188-A | Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor | 杭州医学院 | 2021-12-31 | — | — | CN | disclosed |
| CN-108368107-B | Fused heterocyclic compounds as S1P modulators | 艾伯维公司 | 2021-11-26 | — | — | CN | disclosed |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| EP-3722277-A2 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| CN-111163774-A | Bacterial efflux pump inhibitors | 罗格斯新泽西州立大学 | 2020-05-15 | — | — | CN | disclosed |
| EP-3052464-B1 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| WO-2007070556-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| EP-0838461-B1 | Substituted 2,3-aryl-benzothiophene compounds having estrogenic activity | LILLY CO ELI (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6121293-A | SUCH AS 2-(4-METHOXYPHENYL)-3-(3-(2-(1-PIPERIDINYL)ETHOXY)PHENYL)-6 -METHOXYBENZO(B)THIOPHENE HYDROCHLORIDE; FOR TREATING OSTEOPOROSIS, HYPERLIPIDEMIA, AND ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| US-5843940-A | Benzothiophene compounds, compositions, and method | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0838461-A2 | Substituted 2,3-aryl-benzothiophene compounds having estrogenic activity | ELI LILLY AND COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293553-A1 | P-SELECTIN INHIBITORS AND USES THEREOF | SELP, SELPLG, SELE | MAOB 1787/4885CYP4F2 2737/4885CYP4A11 3078/4885 |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | MAOB 4294/4885CYP4F2 4816/4885CYP4A11 4879/4885 |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | ALK, NPR3, CBR3 | MAOB 2506/4885CYP4F2 1326/4885CYP4A11 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.